Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma

被引：0
|
作者：
Tsukada, Nobuhiro [1 ]
Ikeda, Masahiro [1 ]
Shingaki, Sumito [1 ]
Miyazaki, Kanji [1 ]
Meshitsuka, Sosuke [1 ]
Abe, Yu [1 ]
Yoshiki, Yumiko [1 ]
Suzuki, Kenshi [1 ]
机构：
[1] Japanese Red Cross Med Ctr, Div Hematol, Tokyo, Japan
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2014.11.313
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
270
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [41] A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Khan, Meaghan L.
    Reeder, Craig B.
    Kumar, Shaji K.
    Lacy, Marthy Q.
    Reece, Donna E.
    Dispenzieri, Angela
    Gertz, Morie A.
    Greipp, Phillip
    Hayman, Suzanne
    Zeldenhurst, Steven
    Dingli, David
    Lust, John
    Russell, Stephen
    Laumann, Kristina M.
    Mikhael, Joseph R.
    Bergsagel, P. Leif
    Fonseca, Rafael
    Rajkumar, S. Vincent
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) : 326 - 333
  • [42] Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review
    McCaughan, Georgia J.
    Gandolfi, Sara
    Moore, John J.
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 190 - 204
  • [43] Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
    O'Gorman, Peter
    Laubach, Jacob P.
    O'Dwyer, Michael E.
    Krawczyk, Janusz
    Yee, Andrew J.
    Gilligan, Oonagh
    Cahill, Mary R.
    Rosenblatt, Jacalyn
    Quinn, John
    Murphy, Philip T.
    DiPietro, Heidi
    Perera, Meegahage Ratnakanthi
    Crotty, Gerard M.
    Cummings, Kristen
    Hayden, Patrick J.
    Browne, Paul
    Savell, Alexandra
    O'Leary, Hilary M.
    O'Keeffe, Denis
    Masone, Kelly
    Hennessy, Brian J.
    Garcia, Thomas Guerrero
    Scott, Kathleen
    Saeed, Khalid
    Bianchi, Giada
    Dowling, Paul
    Tierney, Ciara
    Richardson, Paul G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (05) : 562 - 573
  • [44] BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VERSUS BORTEZOMIB-CYCLOPHOSPHAMIDE- DEXAMETHASONE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
    Al-Hashmi, H.
    LEUKEMIA RESEARCH, 2017, 61 : S55 - S55
  • [45] Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
    Wang, Yin-Che
    Lin, Cheng-Hsien
    Su, Yu-Chen
    Teng, Chieh-Lin Jerry
    HEMATOLOGY, 2025, 30 (01)
  • [46] Bortezomib and Dexamethasone Therapy for Newly Diagnosed Patients With Multiple Myeloma Complicated by Renal Impairment
    Li, Jian
    Zhou, Dao-Bin
    Jiao, Li
    Duan, Ming Hui
    Zhang, Wei
    Zhao, Yong Qiang
    Shen, Ti
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (05): : 394 - 398
  • [47] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
    Joseph, Nisha
    Kaufman, Jonathan
    Lonial, Sagar
    Hofmeister, Craig
    Dhodapkar, Madhav
    Gupta, Vikas
    DiCamillo, Sara
    Roberts, Danielle
    Boise, Lawrence
    Nooka, Ajay
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113
  • [48] SUBCUTANEOUS BORTEZOMIB CONTAINING REGIMENS AS UPFRONT TREATMENT OF NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
    Rizzello, I.
    Zamagni, E.
    Dozza, L.
    Quaresima, M.
    Petrucci, M. T.
    De Stefano, V.
    Antonioli, E.
    Tosi, P.
    D'Agostino, M.
    Offidani, M.
    Gozzetti, A.
    Rivoli, G.
    Testoni, N.
    Martello, M.
    Tacchetti, P.
    Pantani, L.
    Mancuso, K.
    Rocchi, S.
    Caratozzolo, I.
    Cavo, M.
    HAEMATOLOGICA, 2019, 104 : 117 - 117
  • [49] Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma?
    Krishnan, Amrita
    LANCET HAEMATOLOGY, 2020, 7 (06): : E445 - E446
  • [50] A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide-Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)
    Sonneveld, Pieter
    Dejoie, Thomas
    Zweegman, Sonja
    Merz, Maximilian
    Weisel, Katja
    Lam, Annette
    Krotneva, Stanimira
    Proskorovsky, Irina
    Kampfenkel, Tobias
    de Boer, Carla
    Cote, Sarah
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E201 - E202
12345